Guggenheim lowered the firm’s price target on Amgen (AMGN) to $340 from $351 and keeps a Neutral rating on the shares. The firm is updating its model following the company’s Q1 earnings release last week.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen Earnings Call Highlights Growth Engines, Tax Risk
- Analyst Reiterates Buy on Amgen After Strong Q1 2026, Raised Guidance and Growing Confidence in MariTide Pipeline
- Amgen Price Target Raised to $425 as Strong Execution and Expanding Pipeline Underpin Maintained Buy Rating
- Amgen price target raised to $307 from $304 at BofA
- Amgen price target raised to $332 from $326 at Morgan Stanley